Drug transporter pharmacogenetics in nucleoside-based therapies.
This article focuses on the different types of transporter proteins that have been implicated in the influx and efflux of nucleoside-derived drugs currently used in the treatment of cancer, viral infections (i.e., AIDS) and other conditions, including autoimmune and inflammatory diseases. Genetic variations in nucleoside-derived drug transporter proteins encoded by the gene families SLC15, SLC22, SLC28, SLC29, ABCB, ABCC and ABCG will be specifically considered. Variants known to affect biological function are summarized, with a particular emphasis on those for which clinical correlations have already been established. Given that relatively little is known regarding the genetic variability of the players involved in determining nucleoside-derived drug bioavailability, it is anticipated that major challenges will be faced in this area of research.
Errasti-Murugarren
Ekaitz
E
The Department of Biochemistry and Molecular Biology, Institute of Biomedicine, University of Barcelona, Diagonal 645, 08028 Barcelona, Spain.
Pastor-Anglada
Marçal
M
D001682:Biological Availability; D002352:Carrier Proteins / Q000235:genetics*; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D015394:Molecular Structure; D009705:Nucleosides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D010597:Pharmacogenetics; D013379:Substrate Specificity
D002352:Carrier Proteins; D009705:Nucleosides